微小 RNA-148a 靶向非小细胞肺癌患者的 Bcl-2。
Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer.
机构信息
Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt.
Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt.
出版信息
Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1949-1955. doi: 10.31557/APJCP.2021.22.6.1949.
OBJECTIVE
Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide. MicroRNAs regulate more than 60% of human genes, including tumor suppressor genes and oncogenes. Accordingly, they can affect cancer risk. This study aimed to evaluate the role of serum miR-148a as a non-invasive biomarker in non-small cell lung cancer (NSCLC) patients and to assess the correlation between miR-148a and Bcl-2, as one of its target proteins.
MATERIALS AND METHODS
A total of 50 newly diagnosed NSCLC cases and 30 apparently healthy controls were recruited in this study. MiR-148a level was measured by TaqMan- Real time RT-PCR assay and Bcl-2 level was measured by ELISA.
RESULTS
Significant lower expression of serum miR-148a and higher serum Bcl-2 levels were observed in NSCLC patients as compared to the control group (p.
目的
肺癌是最常见的癌症之一，也是全球癌症相关死亡的主要原因。 microRNAs 调节超过 60%的人类基因，包括肿瘤抑制基因和癌基因。因此，它们可以影响癌症风险。本研究旨在评估血清 miR-148a 作为非小细胞肺癌 (NSCLC) 患者非侵入性生物标志物的作用，并评估 miR-148a 与 Bcl-2 之间的相关性，Bcl-2 是其靶蛋白之一。
材料和方法
本研究共招募了 50 例新诊断的 NSCLC 病例和 30 例健康对照者。采用 TaqMan-Real time RT-PCR 法检测 miR-148a 水平，ELISA 法检测 Bcl-2 水平。
结果
与对照组相比，NSCLC 患者血清 miR-148a 表达水平显著降低，血清 Bcl-2 水平显著升高（p<0.001）。
Zotero 插件